Orchid Pharma gets EIR report from USFDA on inspection closure
New Delhi: Drug firm Orchid Pharma has received Establishment Inspection Report (EIR) from the US health regulator on the successful inspection closure for its Irungattukottai formulations plant in Tamil Nadu.
Reacting to the news, shares of the company jumped by 9.91 per cent to settle the day at Rs 64.90.
"Orchid received the Establishment Inspection Report (EIR) from United States Food and Drug Administration (USFDA) based on the successful inspection closure for the formulation manufacturing facility," at Irungattukottai, the company said in a BSE filing.
The facility was inspected by the USFDA in the month of May 2015, it added.
Establishment Inspection Report (EIR) is given to a establishment after the completion of the inspection by FDA.
Orchid is present in segments such as anti-infectives, anti-inflammatory, central nervous system, cardio vascular, nutraceuticals and oral as well as sterile products.
Reacting to the news, shares of the company jumped by 9.91 per cent to settle the day at Rs 64.90.
"Orchid received the Establishment Inspection Report (EIR) from United States Food and Drug Administration (USFDA) based on the successful inspection closure for the formulation manufacturing facility," at Irungattukottai, the company said in a BSE filing.
The facility was inspected by the USFDA in the month of May 2015, it added.
Establishment Inspection Report (EIR) is given to a establishment after the completion of the inspection by FDA.
Orchid is present in segments such as anti-infectives, anti-inflammatory, central nervous system, cardio vascular, nutraceuticals and oral as well as sterile products.
Next Story
